Two medicines, side by side
Hydrochlorothiazide/triamterene vs propranolol
Hydrochlorothiazide/triamterene and propranolol are both labeled for high blood pressure. Drugs@FDA records approvals of hydrochlorothiazide/triamterene since 1965 and of propranolol since 1967. Pharmacies paid $0.0969 per triamterene-hydrochlorothiazide 37.5-25 mg tablet and $0.0493 per propranolol 20 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, hydrochlorothiazide/triamterene is a potassium-sparing diuretic and propranolol a beta-adrenergic blocker.
Check it at the source: the hydrochlorothiazide/triamterene FDA label on DailyMed (effective February 17, 2026); the propranolol FDA label on DailyMed (effective January 15, 2026).
Highlights of the hydrochlorothiazide and triamterene record
Hydrochlorothiazide and triamterene (Dyazide) · label of February 17, 2026
Used for
From the label: indicationsThis fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. […]
On the market
- Earliest approval on file
- December 2, 1965
- Generic labelers
- 24 labelers
- Pharmacy cost
- $0.0969 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 5
Highlights of the propranolol record
Propranolol (Inderal) · label of January 15, 2026
Used for
From the label: indicationsHypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. […]
On the market
- Earliest approval on file
- November 13, 1967
- Generic labelers
- 42 labelers
- Pharmacy cost
- $0.0493 per tablet
Supply and safety
- Shortage
- In shortage
- Recalls
- 4
Source: FDA drug labels via openFDA (Hydrochlorothiazide/triamterene label of February 17, 2026, Propranolol label of January 15, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do hydrochlorothiazide/triamterene and propranolol differ on the record?
In FDA's classes, hydrochlorothiazide/triamterene is a potassium-sparing diuretic and propranolol a beta-adrenergic blocker.
Generics: hydrochlorothiazide/triamterene since 1987; propranolol since 1985 (Drugs@FDA).
| Hydrochlorothiazide/triamterene | Propranolol | |
|---|---|---|
| Labeled for | High blood pressure, Edema (fluid retention) | High blood pressure, Angina, Atrial fibrillation, Migraine |
| Pharmacologic class | Potassium-sparing Diuretic, Thiazide Diuretic | beta-Adrenergic Blocker |
| How it works (label) | n/a | Mechanism of Action The mechanism of the antihypertensive effect of propranolol has not been established. |
| Half-life (label) | n/a | The plasma half-life of propranolol is from 3 to 6 hours. |
| Earliest approval on file (Drugs@FDA) | December 2, 1965 | November 13, 1967 |
| First generic approved | December 8, 1987 | July 30, 1985 |
| Generic labelers (NDC) | 24 labelers | 42 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0969 per tablet (Triamterene-hydrochlorothiazide 37.5-25 mg tablet) | $0.0493 per tablet (Propranolol 20 mg tablet) |
| 12-month price change | +6% | -17% |
| Boxed warning | No | No |
| Shortage now | No current entry | In shortage |
| Recalls recorded | 5 | 4 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,109 | 71,660 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to hydrochlorothiazide/triamterene
- every medicine labeled for the same conditions